search
Back to results

Reducing Use of Sleep Medications Assisted by a Digital Insomnia Intervention (SEDATIVE)

Primary Purpose

Insomnia

Status
Recruiting
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Cognitive Behavioral Therapy for Insomnia
Deprescribing
Sponsored by
VA Office of Research and Development
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Insomnia focused on measuring Insomnia, Veterans, Hypnotics and Sedatives, Deprescribing, Cognitive Behavioral Therapy for Insomnia, Telemedicine, Mobile Applications

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • A Veteran receiving care at VA Pittsburgh Healthcare System
  • Active sedative-hypnotic medication use >14 days/month for >=3 months
  • A desire to reduce or stop using sedative-hypnotic medications
  • Access to a mobile device with internet

Exclusion Criteria:

  • A disorder that would impair participation (e.g., cancer, uncontrolled pain, severe depression)
  • A disorder that can be exacerbated by changes in sleep (e.g., seizure disorder, bipolar I disorder)
  • High risk of suicide
  • An active substance use disorder in past 6 months

Sites / Locations

  • VA Pittsburgh Healthcare System University Drive Division, Pittsburgh, PARecruiting

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

COAST + Deprescribing

Arm Description

CBT-I with simultaneous sedative-hypnotic deprescribing delivered through a digital platform

Outcomes

Primary Outcome Measures

Insomnia Severity Index (ISI) Change
Total score (0-28): no insomnia (0-7); sub-threshold (8-14); moderate (15-21); and severe insomnia (22-28). A reduction pre- to post-treatment/follow-up of 8 points (or more) indicate a treatment response and a post-treatment/follow-up score or 7 (or less) indicate remission.
Sedative-Hypnotic Medication Use Change
T0, Baseline: medication name, dose, frequency of use (# nights/week) T1, Post-treatment: medication name, dose, frequency of use (# nights/week), >=50% reduction from baseline (yes/no); cessation (yes/no) T2, 3-month follow-up: medication name, dose, frequency of use (# nights/week), >=50% reduction from baseline (yes/no); cessation (yes/no)

Secondary Outcome Measures

Sleep Diary - Sleep Onset Latency (SOL) Change
The Sleep Diary measures common sleep variables important for tracking and changing sleep behaviors: Sleep Onset Latency (SOL) is the subjective estimate of time it takes to fall asleep after going to bed and turning the lights out (or attempting to go to sleep). SOL is measured in minutes (lower values are better).
Sleep Diary - Wake After Sleep Onset (WASO) Change
The Sleep Diary measures common sleep variables important for tracking and changing sleep behaviors: Wake After Sleep Onset (WASO) is the subjective estimate of time awake in the middle of the night, after falling asleep and before final rise time/out of bed. WASO is measured in minutes (lower values are better).
Sleep Diary - Sleep Efficiency Change
The Sleep Diary measures common sleep variables important for tracking and changing sleep behaviors: Sleep Efficiency (SE) = (total sleep time [TST] / time in bed [TIB]) x 100. SE is measured as a percentage (range 0-100%; higher values are better).
Patient-Reported Outcomes Measurement Information System Adult Profile (PROMIS 29+2) Change
The PROMIS 29+2 includes measures of Physical Function, Social Roles, Anxiety, Depression, Fatigue, Sleep Disturbance, Pain Interference, Pain Intensity, and Cognitive Function. Each construct is scored individually (4 items, range 4-20) except Cognitive Function (2 items, range 2-10). A higher PROMIS T-score represents more of the concept being measured. For negatively-worded concepts like Anxiety, a T-score of 60 is one SD worse than average. By comparison, an Anxiety T-score of 40 is one SD better than average. However, for positively-worded concepts like Physical Function-Mobility, a T score of 60 is one SD better than average while a T-score of 40 is one SD worse than average. When all constructs are scored together, a preference score is calculated, representing health-related quality of life ranging from 0 (as bad as dead) to 1 (perfect or ideal health).

Full Information

First Posted
August 20, 2021
Last Updated
September 5, 2023
Sponsor
VA Office of Research and Development
search

1. Study Identification

Unique Protocol Identification Number
NCT05027438
Brief Title
Reducing Use of Sleep Medications Assisted by a Digital Insomnia Intervention
Acronym
SEDATIVE
Official Title
SEdative-Hypnotic Deprescribing Assisted by a Technology-Driven Insomnia InterVEntion (SEDATIVE)
Study Type
Interventional

2. Study Status

Record Verification Date
September 2023
Overall Recruitment Status
Recruiting
Study Start Date
September 22, 2022 (Actual)
Primary Completion Date
February 29, 2024 (Anticipated)
Study Completion Date
April 30, 2024 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
VA Office of Research and Development

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Product Manufactured in and Exported from the U.S.
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
Chronic insomnia is one of the most common health problems among Veterans and significantly impacts their health, function, and quality of life. Sedative-hypnotic medications are the most common treatment despite mixed effectiveness and are associated with numerous risks that can further impact Veteran function. An intervention combining evidence-based interventions for deprescribing sedative-hypnotics and behavioral interventions for insomnia can help to optimize sleep and functional outcomes for Veterans with a desire to reduce or stop using these medications. Furthermore, by delivering these interventions through an easy to use and highly accessible digital platform can provide additional benefits to Veterans, especially those with limited time and access to engage in traditional in-person interventions. The Clinician Operated Assistive Sleep Technology (COAST) is an efficient, scalable, and adaptable platform that can help providers to reach more Veterans and provide evidence-based care that translates to improved health and function. Aim 1: To assess the feasibility of recruiting Veterans with chronic sedative-hypnotic use to participate in a 12-week combined deprescribing and CBT-I intervention, delivered through the COAST digital platform. Aim 2: To assess Veteran acceptability and usability of the COAST platform. Aim 3: To assess change in Veteran sleep, sedative-hypnotic use, and function pre- to post-intervention.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Insomnia
Keywords
Insomnia, Veterans, Hypnotics and Sedatives, Deprescribing, Cognitive Behavioral Therapy for Insomnia, Telemedicine, Mobile Applications

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Model Description
pre-post design
Masking
None (Open Label)
Allocation
N/A
Enrollment
50 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
COAST + Deprescribing
Arm Type
Experimental
Arm Description
CBT-I with simultaneous sedative-hypnotic deprescribing delivered through a digital platform
Intervention Type
Behavioral
Intervention Name(s)
Cognitive Behavioral Therapy for Insomnia
Other Intervention Name(s)
CBT-I
Intervention Description
A multimodal psychotherapy that may include stimulus control, sleep restriction, cognitive therapy, psychoeducation, and relaxation strategies
Intervention Type
Behavioral
Intervention Name(s)
Deprescribing
Other Intervention Name(s)
Gradual Dose Reduction, Tapering
Intervention Description
The reduction or withdrawal of a medication, through gradual dose reduction, managed by a healthcare professional that aims to reduce harm and improve outcomes
Primary Outcome Measure Information:
Title
Insomnia Severity Index (ISI) Change
Description
Total score (0-28): no insomnia (0-7); sub-threshold (8-14); moderate (15-21); and severe insomnia (22-28). A reduction pre- to post-treatment/follow-up of 8 points (or more) indicate a treatment response and a post-treatment/follow-up score or 7 (or less) indicate remission.
Time Frame
baseline (T0; week 0), post-treatment (T1; week 12), 3 month follow-up (T2; week 24)
Title
Sedative-Hypnotic Medication Use Change
Description
T0, Baseline: medication name, dose, frequency of use (# nights/week) T1, Post-treatment: medication name, dose, frequency of use (# nights/week), >=50% reduction from baseline (yes/no); cessation (yes/no) T2, 3-month follow-up: medication name, dose, frequency of use (# nights/week), >=50% reduction from baseline (yes/no); cessation (yes/no)
Time Frame
baseline (T0; week 0), post-treatment (T1; week 12), 3 month follow-up (T2; week 24)
Secondary Outcome Measure Information:
Title
Sleep Diary - Sleep Onset Latency (SOL) Change
Description
The Sleep Diary measures common sleep variables important for tracking and changing sleep behaviors: Sleep Onset Latency (SOL) is the subjective estimate of time it takes to fall asleep after going to bed and turning the lights out (or attempting to go to sleep). SOL is measured in minutes (lower values are better).
Time Frame
baseline (T0; week 0), post-treatment (T1; week 12), 3 month follow-up (T2; week 24)
Title
Sleep Diary - Wake After Sleep Onset (WASO) Change
Description
The Sleep Diary measures common sleep variables important for tracking and changing sleep behaviors: Wake After Sleep Onset (WASO) is the subjective estimate of time awake in the middle of the night, after falling asleep and before final rise time/out of bed. WASO is measured in minutes (lower values are better).
Time Frame
baseline (T0; week 0), post-treatment (T1; week 12), 3 month follow-up (T2; week 24)
Title
Sleep Diary - Sleep Efficiency Change
Description
The Sleep Diary measures common sleep variables important for tracking and changing sleep behaviors: Sleep Efficiency (SE) = (total sleep time [TST] / time in bed [TIB]) x 100. SE is measured as a percentage (range 0-100%; higher values are better).
Time Frame
baseline (T0; week 0), post-treatment (T1; week 12), 3 month follow-up (T2; week 24)
Title
Patient-Reported Outcomes Measurement Information System Adult Profile (PROMIS 29+2) Change
Description
The PROMIS 29+2 includes measures of Physical Function, Social Roles, Anxiety, Depression, Fatigue, Sleep Disturbance, Pain Interference, Pain Intensity, and Cognitive Function. Each construct is scored individually (4 items, range 4-20) except Cognitive Function (2 items, range 2-10). A higher PROMIS T-score represents more of the concept being measured. For negatively-worded concepts like Anxiety, a T-score of 60 is one SD worse than average. By comparison, an Anxiety T-score of 40 is one SD better than average. However, for positively-worded concepts like Physical Function-Mobility, a T score of 60 is one SD better than average while a T-score of 40 is one SD worse than average. When all constructs are scored together, a preference score is calculated, representing health-related quality of life ranging from 0 (as bad as dead) to 1 (perfect or ideal health).
Time Frame
baseline (T0; week 0), post-treatment (T1; week 12), 3 month follow-up (T2; week 24)

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: A Veteran receiving care at VA Pittsburgh Healthcare System Active sedative-hypnotic medication use >14 days/month for >=3 months A desire to reduce or stop using sedative-hypnotic medications Access to a mobile device with internet Exclusion Criteria: A disorder that would impair participation (e.g., cancer, uncontrolled pain, severe depression) A disorder that can be exacerbated by changes in sleep (e.g., seizure disorder, bipolar I disorder) High risk of suicide An active substance use disorder in past 6 months
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Adam D Bramoweth, PhD
Phone
(412) 360-2806
Email
Adam.Bramoweth@va.gov
First Name & Middle Initial & Last Name or Official Title & Degree
Caroline E Hough, BA
Phone
(412) 360-2364
Email
caroline.hough@va.gov
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Adam D. Bramoweth, PhD
Organizational Affiliation
VA Pittsburgh Healthcare System University Drive Division, Pittsburgh, PA
Official's Role
Principal Investigator
Facility Information:
Facility Name
VA Pittsburgh Healthcare System University Drive Division, Pittsburgh, PA
City
Pittsburgh
State/Province
Pennsylvania
ZIP/Postal Code
15240
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Adam D Bramoweth, PhD
Phone
412-360-2806
Email
Adam.Bramoweth@va.gov
First Name & Middle Initial & Last Name & Degree
Adam D. Bramoweth, PhD

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Reducing Use of Sleep Medications Assisted by a Digital Insomnia Intervention

We'll reach out to this number within 24 hrs